恒瑞医药：子公司HRS-6257片临床试验获批

Core Viewpoint - The company announced that its subsidiary, Shanghai Hengrui Medicine Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of HRS-6257 tablets, which will be conducted for postoperative analgesia [1] Group 1 - The clinical trial approval indicates that the application for HRS-6257 tablets meets the relevant requirements for drug registration [1] - HRS-6257 tablets are intended for the treatment of acute and chronic pain [1]